Gene therapy for colorectal cancer

被引:4
作者
Kerr, DJ [1 ]
Seymour, LW [1 ]
Maruta, F [1 ]
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England
关键词
cancer treatment; colorectal cancer; gene therapy; immunotherapy; prodrug therapy; tumour targeting; vector;
D O I
10.1517/14712598.3.5.779
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Colorectal cancer is an important public health problem worldwide. Gene therapy has therapeutic potential for patients with advanced or recurrent colorectal cancer, incurable by conventional treatments. To date, many strategies of gene therapy have been explored, including mutant gene correction, prodrug activation, immune stimulation and genetically-modified oncolytic viruses. Although the preclinical results, of gene therapy for colorectal cancer have shown promise, gene therapy is still at an early stage of clinical development and has not yet shown a significant therapeutic benefit for patients. The main obstacles for introduction of gene therapy to patients are poor targeting selectivity of the vectors and inefficient gene transfer. As the science supporting tumour-selective vectors evolves, gene therapy may expand rapidly in the clinical practice of colorectal cancer treatment.
引用
收藏
页码:779 / 788
页数:10
相关论文
共 56 条
  • [11] Conry RM, 2000, CLIN CANCER RES, V6, P34
  • [12] Phase I study of direct administration of a replication deficient adenovirus vector containing the E-coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
    Crystal, RG
    Hirschowitz, E
    Lieberman, M
    Daly, J
    Kazam, E
    Henschke, C
    Yankelevitz, D
    Kemeny, N
    Silverstein, R
    Ohwada, A
    Russi, T
    Mastrangeli, A
    Sanders, A
    Cooke, J
    Harvey, BG
    [J]. HUMAN GENE THERAPY, 1997, 8 (08) : 985 - 1001
  • [13] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [14] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    Douillard, JY
    Cunningham, D
    Roth, AD
    Navarro, M
    James, RD
    Karasek, P
    Jandik, P
    Iveson, T
    Carmichael, J
    Alakl, M
    Gruia, G
    Awad, L
    Rougier, P
    [J]. LANCET, 2000, 355 (9209) : 1041 - 1047
  • [15] Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden
    Edwards, BK
    Howe, HL
    Ries, LAG
    Thun, MJ
    Rosenberg, HM
    Yancik, R
    Wingo, PA
    Jemal, A
    Feigal, EG
    [J]. CANCER, 2002, 94 (10) : 2766 - 2792
  • [16] Colorectal carcinoma: radiological diagnosis and staging
    Elmas, N
    Killi, RM
    Sever, A
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2002, 42 (03) : 206 - 223
  • [17] CYTOKINE GENE-THERAPY WITH INTERLEUKIN-2-TRANSDUCED FIBROBLASTS - EFFECTS OF IL-2 DOSE ON ANTITUMOR IMMUNITY
    FAKHRAI, H
    SHAWLER, DL
    GJERSET, R
    NAVIAUX, RK
    KOZIOL, J
    ROYSTON, I
    SOBEL, RE
    [J]. HUMAN GENE THERAPY, 1995, 6 (05) : 591 - 601
  • [18] A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS
    FEARON, ER
    VOGELSTEIN, B
    [J]. CELL, 1990, 61 (05) : 759 - 767
  • [19] INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE
    FEARON, ER
    PARDOLL, DM
    ITAYA, T
    GOLUMBEK, P
    LEVITSKY, HI
    SIMONS, JW
    KARASUYAMA, H
    VOGELSTEIN, B
    FROST, P
    [J]. CELL, 1990, 60 (03) : 397 - 403
  • [20] FERLAY J, 2001, IARC CARNCERBASE